3/31
08:42 am
avxl
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
3/30
07:38 am
avxl
Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]
3/30
07:30 am
avxl
Anavex Life Sciences Provides Comprehensive Regulatory Update
Medium
Report
Anavex Life Sciences Provides Comprehensive Regulatory Update
3/26
10:02 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
3/26
08:50 am
avxl
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation [Yahoo! Finance]
3/25
07:30 am
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
High
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
3/23
10:52 am
avxl
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
3/23
07:30 am
avxl
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
High
Report
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
3/17
08:13 am
avxl
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference [Yahoo! Finance]
3/17
07:30 am
avxl
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Medium
Report
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
3/5
08:42 am
avxl
Anavex Life Sciences Touts Oral Alzheimer's Drug Blarcamesine Data, Cash Runway at Healthcare Conference [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Touts Oral Alzheimer's Drug Blarcamesine Data, Cash Runway at Healthcare Conference [Yahoo! Finance]
3/3
07:30 am
avxl
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
Medium
Report
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
2/25
07:42 am
avxl
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference [Yahoo! Finance]
Low
Report
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference [Yahoo! Finance]
2/25
07:30 am
avxl
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Low
Report
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
2/23
07:30 am
avxl
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
Low
Report
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
2/10
08:05 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/10
05:36 am
avxl
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [Seeking Alpha]
Medium
Report
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [Seeking Alpha]
2/9
02:45 pm
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
2/9
10:16 am
avxl
Anavex Life Sciences Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Anavex Life Sciences Q1 Earnings Call Highlights [Yahoo! Finance]
2/9
07:41 am
avxl
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
2/9
07:30 am
avxl
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Low
Report
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
2/3
08:18 am
avxl
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 [Yahoo! Finance]
Low
Report
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 [Yahoo! Finance]
2/3
07:30 am
avxl
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Low
Report
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
1/15
04:33 am
avxl
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
Low
Report
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
1/13
07:30 am
avxl
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Medium
Report
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease